STOCK TITAN

NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction

(Neutral)
Tags
conferences

NEXGEL (NASDAQ:NXGL) rescheduled its shareholder update conference call to April 23, 2026 at 4:30 P.M. ET to provide an update on the proposed transaction with Celularity.

The company said it will not finance the transaction under its previously announced Securities Purchase Agreement and is negotiating a new financing with a different investor group; additional details are expected on April 23.

Call details include U.S. toll-free 1-800-267-6316, international 1-203-518-9783, and a webcast via Events and Presentations.

Loading...
Loading translation...

Positive

  • Shareholder call set for April 23, 2026
  • Negotiating new financing with a different investor group
  • Company to provide additional transaction details on April 23

Negative

  • The company stated no assurance the Celularity transaction will close
  • Will not use previously announced Securities Purchase Agreement financing

News Market Reaction – NXGL

-15.26% 6.6x vol
36 alerts
-15.26% Session close to close
+21.8% Peak Tracked
-3.8% Trough Tracked
$6.53M Market Cap
6.6x Rel. Volume

In the Apr 16 session, NXGL declined 15.26%, reflecting a significant negative market reaction. Argus tracked a peak move of +21.8% during that session. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 36 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 6.6x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

LANGHORNE, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its shareholder update conference call to April 23, 2026, at 4:30 P.M. ET.

While there is no assurance that the Celularity transaction will close, the Company will not be financing the transaction under its previously announced Securities Purchase Agreement with a certain institutional investor. The Company is in the process of negotiating a new agreement with a different group of investors under a new financing structure. The Company anticipates providing additional details regarding this proposed transaction with Celularity Inc. on April 23rd.

Shareholder Update Conference Call Details:
Date: April 23, 2026
Time: 4:30 P.M. ET
Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)
Webcast: Events and Presentations

About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “attempt,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our ability to consummate the potential acquisition and the related additional investment. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com


FAQ

When will NEXGEL (NXGL) provide an update on the Celularity transaction?

NEXGEL will provide an update on April 23, 2026 at 4:30 P.M. ET. According to the company, the shareholder update conference call will include details on the proposed transaction and financing status.

How is NEXGEL (NXGL) financing the Celularity transaction after the change?

NEXGEL is negotiating a new financing arrangement with a different investor group. According to the company, it will not use the previously announced Securities Purchase Agreement and expects to discuss the new structure on April 23.

What did NEXGEL (NXGL) say about the certainty of the Celularity deal closing?

The company said there is no assurance the Celularity transaction will close. According to the company, talks are ongoing and the outcome remains uncertain pending finalized agreements.

How can investors join the NEXGEL (NXGL) shareholder update call on April 23, 2026?

Investors can join via U.S. toll-free 1-800-267-6316, international 1-203-518-9783, or the webcast. According to the company, the webcast will be available under Events and Presentations on its site.

What changed from NEXGEL's prior financing plan for the Celularity transaction?

NEXGEL stated it will not finance the deal under the previously announced Securities Purchase Agreement. According to the company, it is instead negotiating with a different group under a new financing structure.